ArticleBMC surgery2026
Construction and metabolic efficacy evaluation of sleeve gastrectomy and modified Roux-en-Y gastric bypass in a mouse model with obesity and MASLD.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionObesity and related metabolic diseases are major global health challenges. Metabolic and bariatric surgery (MBS) is an effective treatment. Yet exploring its molecular mechanisms remains limite due to the challenge of obtaining postoperative tissue samples. While rat models are more convenient in size and operation, mouse models offer unique advantages such as lower breeding costs and easier genetic modification. However, research on mouse MBS models is still limited because of their small size and surgical complexity, highlighting the need for optimized techniques to advance the field.
objectiveThis study aims to establish a high-fat diet-induced (HFD) obesity combined with metabolic dysfunction-associated steatotic liver disease (MASLD) mouse model, and to evaluate the MBS models assisted by microsurgery, so as to provide a reliable tool for mechanism research.
methodsMale SPF C57BL/6J mice were randomly assigned to the normal diet (ND) group and the HFD group. The mouse in the HFD group were induced to develop obesity with MASLD through a high-fat diet for 16 weeks. The HFD group was further divided into sham operation group (Sham), sleeve gastrectomy (SG) group, and modified Roux-en-Y gastric bypass (RYGB) group (n = 6). Metabolic efficacy was evaluated by weight, metabolic parameters, and pathological staining analysis at the 4th week post-surgery.
resultsCompared with the ND group, the weight of the HFD group increased by 38.25% (P < 0.001), and the liver tissue showed pathological features of MASLD. Compared with the Sham group, the weight of the SG group and the modified RYGB group decreased significantly at 4 weeks after operation (P < 0.05). Compared with the Sham group, the insulin sensitivity of the RYGB group was improved. Hepatic steatosis was significantly reduced in SG and RYGB groups, and serum TG and LDL levels were significantly improved. The postoperative survival rate of SG and Sham mice was 100%, and RYGB was 83.3% (1 case died of anastomotic stenosis).
conclusionThe establishment of a modified RYGB and SG mouse model has good reproducibility, safety, and efficacy. This study provides a useful tool for exploring the mechanism of MBS in the treatment of obesity with MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.